Y2 Solution KRX:011690KOSPI
와이투솔루션 · Korean news coverage and regulatory filings, organized.
Articles, 24h3
Articles, 7 days6
DART filings, 7 days0
Articles tracked10since Sep 11
In Q2 2026, Y2 Solution reported revenue of ₩87.4bn, up 172.4% year on year, and operating profit of ₩665m. Y2 Solution (와이투솔루션) appeared in 6 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Oct 29 with 5 articles. The most common catalyst was contracts & orders (1).
Filing signals Turnaround Revenue +30% Screener
Y2 Solution quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩87.4bn | +172.4% | ₩665m margin 0.8% | ₩448m |
| Q1 2026 | ₩86.7bn | +127.6% | ₩954m margin 1.1% | −₩649m |
| Q4 2025 derived | ₩48.3bn | +36.5% | −₩1.2bn margin −2.4% | −₩4.5bn |
| Q3 2025 | ₩46.6bn | +17.9% | −₩938m margin −2.0% | −₩1.0bn |
| Q2 2025 | ₩32.1bn | -17.7% | −₩1.4bn margin −4.4% | −₩4.8bn |
| Q1 2025 | ₩38.1bn | -6.3% | ₩933m margin 2.4% | ₩782m |
| Q4 2024 derived | ₩35.4bn | – | −₩336m margin −0.9% | ₩37m |
| Q3 2024 | ₩39.5bn | +0.8% | ₩638m margin 1.6% | −₩866m |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Y2 Solution top stories 2 weeks, by number of outlets
- 1
- 2
- 3
- 4
- 5
Latest Y2 Solution news Korean headlines
-
와이투솔루션, 美 합작사 건성 황반변성 세포치료제 임상 ‘청신호’…2년간 시력개선 유지
1 more on this story · 1 outlets
- 와이투솔루션, 건성 황반변성 세포치료제 임상서 시력개선 2년 유지블로터 · Oct 29 15:04
-
와이투솔루션, BIX 2026서 美 룩사 건성 황반변성 세포치료제 임상 1/2a상 결과 발표
2 more on this story · 2 outlets
- 와이투솔루션 "美 합작사 룩사, BIX 2026서 황반변성 임상 1/2a상 결과 발표"뉴스핌 · Oct 13 11:10
- 와이투솔루션, ‘BIX 2026’서 건성 황반변성 세포치료제 임상 1/2a상 결과 발표이투데이 · Oct 13 13:50